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European Medicines Agency and the European network for Health
Technology Assessment initiated a collaboration with the aim to
improve the contribution regulatory assessment reports can make to
the assessment of relative effectiveness of medicinal products by health
technology assessment bodies. This collaboration on improving Euro-
pean Public Assessment Reports (EPARs) started in February 2010 and
was performed over 2 years. As a result, the templates for preparing
EPARs were revised to better address the needs of heath technology
organizations. The better understanding of information needs was a key
outcome of the collaboration. To ascertain whether these template
changes led to the inclusion of relevant information, a review of a smallee front matter Copyright & 2014, International S
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ndence to: Michael Berntgen, European Medicinesset of EPARs for recently approved medicinal products was carried out in
parallel by both the European network for Health Technology Assess-
ment and the European Medicines Agency. This report provides an
account of this project on improving EPARs, which is part of the ongoing
dialogue between regulators and health technology assessment bodies
on a European level to support policymaker decisions in the future.
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Scientiﬁc evaluation of the clinical data produced during drug
development can be intended to estimate the beneﬁt/risk ratio of
the product (recently in some jurisdictions also referred to as beneﬁt/
harm/uncertainty), for the purpose of marketing authorization, or to
estimate the effectiveness of the new product as compared with
existing therapies, as part of the health technology assessment (HTA)
process to support decision making on price and reimbursement.
The European Medicines Agency (EMA) is responsible for the
scientiﬁc evaluation of applications for European Union (EU)
marketing authorizations for medicinal products in the so-
called centralized procedure. Under this procedure, a single
marketing-authorization application is submitted to the EMA
and once authorization is granted by the European Commission
on the basis of a pan-European scientiﬁc assessment of quality,
efﬁcacy, and safety by EMA committees, a centralized marketing
authorization is valid in all EU member states.The subsequent evaluation and decision-making process lead-
ing to decisions on the pricing and reimbursement of medicinal
products lie with the national bodies. HTA is a multidisciplinary
process that summarizes information about the medical, social,
economic, and ethical issues related to the use of a health
technology in a systematic, transparent, unbiased, and robust
manner. Its aim is to inform the formulation of safe, effective
health policies that are patient focused and seek to achieve best
value [1]. Criteria for HTA vary between countries, but generally
HTA bodies in Europe use relative effectiveness assessment (REA),
a European equivalent to comparative effectiveness research in
the United States, as part of the HTA process [2].
The European network for Health Technology Assessment
(EUnetHTA) is a network of organizations appointed by EU
member states that produce or contribute to HTA to facilitate
efﬁcient use of resources available for HTA, to create a sustain-
able system of HTA knowledge sharing, and to promote good
practice in HTA methods and processes [1,3]. Originally started asociety for Pharmacoeconomics and Outcomes Research (ISPOR).
uthor(s) and may not be understood or quoted as being made on
or one of its committees or working parties.
Agency, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK.
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and sustainable network for HTA across Europe [4].
In October 2008, the Pharmaceutical Forum, a high-level min-
isterial platform for discussion between member states, EU insti-
tutions, industry, health care professionals, patients, and insurance
funds, agreed on conclusions and recommendations to ﬁnd rele-
vant solutions to public health considerations regarding pharma-
ceuticals, while ensuring the competitiveness of the industry and
the sustainability of the national health care systems [5]. One of
these recommendations provided a political mandate to initiate
collaboration between the EMA and EUnetHTA with the aim to
improve the availability and best use of data relevant to HTA.
Speciﬁcally, the objective of this joint project of regulators and HTA
bodies was to “consider how information in the European Public
Assessment Report /…/ can further contribute to relative effective-
ness assessment” [5].
The regulatory assessment reports, which are the basis for
central marketing authorizations, are publicly available as so-
called European Public Assessment Reports (EPARs). EPARs reﬂect
the scientiﬁc conclusions reached by the EMA’s Committee for
Medicinal Products for Human Use (CHMP) at the end of the
regulatory review process after deletion of commercially conﬁden-
tial information. These are published on the EMA’s Web site for
every medicine authorized through the centralized procedure in
the EU. Because these contain the CHMP’s judgment on the
methodological quality of the studies and the relevance and
signiﬁcance of results, in the perspective of the estimate of the
balance between favorable and unfavorable effects for the medic-
inal product, they may also be used as source documents for REAs
from the HTA perspective. In particular, such assessment reports
are used in the context of rapid REA of pharmaceuticals [6].
The collaboration between the EMA and EUnetHTA on EPARs
started in February 2010 and was performed over 2 years. It has
been subject to a wider consultation within EUnetHTA as part of
the Work Package 5 on REA of Pharmaceuticals of EUnetHTA Joint
Action 1. This report provides an account of various activities as
part of the project to address the recommendation on improving
the EPAR.Methods
In the ﬁrst phase, EUnetHTA provided input on the usefulness of
published EPARs and Summary of Product Characteristics (SmPC)
in the context of REA of medicinal products based on the initial
work performed in 2009 by some partners (which are also
EUnetHTA partners) of the Medicine Evaluation Committee
(MEDEV), a standing working group of the European Social Health
Insurance Forum. This input was reviewed by the EMA and an
action plan was established, which was mutually agreed between
the EMA and EUnetHTA. Subsequently, the templates and guidance
documents for the assessment of initial marketing authorization
applications were amended by the EMA to implement the agreed
improvements through either speciﬁc sections or supportive guid-
ance. The revised templates and guidance documents were pre-
sented to the CHMP for adoption and subsequently published on
the EMA’s Web site (www.ema.europa.eu) for use by assessors in
the centralized procedure (4Home 4Regulatory 4Human medi-
cines 4Pre-authorisation 4Templates for assessors).
The second phase was the critical review of EPARs to establish
compliance with revised templates. For this purpose, EPARs of the
ﬁrst 10 products, for which the assessment report has been
prepared after the revised templates came into operation, were
analyzed for compliance with speciﬁc aspects amended in the
template. The following EPARs were reviewed: Esbriet (pirfeni-
done), Gilenya (ﬁngolimod), Halaven (eribulin), Jevtana (cabazi-
taxel), Pravafenix (fenoﬁbrate/pravastatin), Pumarix (pandemicinﬂuenza vaccine [H5N1]), Teysuno (tegafur/gimeracil/oteracil),
Trobalt (retigabine), Xeplion (paliperidone), and Xiapex (collage-
nase clostridium histolyticum). The review took place in second
and third quarters of 2011 on the basis of the publicly available
EPARs. A questionnaire with 36 questions was developed by the
EMA targeting the identiﬁed areas for improvement. Two types of
answers were attributed depending on the nature of the question:
either the option “yes/no/not applicable” (13 questions) if the
underlying question was simply whether an item is included or
the grading “excellent/good/could be improved/no/not applicable”
(23 questions) if a more differentiated review was considered
more meaningful. Table 1 indicates for each review item the type
of question. Numerical values were assigned against the answers
(“1/0” and “3/2/1/0” for binary and graded answers, respectively) to
allow for statistical analysis of compliance of the EPARs for each
individual question. The review of the 10 EPARs was performed in
parallel by the EMA and by EUnetHTA, always involving two
reviewers per organization and using the same questionnaire
and numerical scales. In case of divergent views between the
two reviewers, consensus was formed. One additional question on
the beneﬁt-risk assessment was added by HTA organizations at
the time of EUnetHTA review. As regards EUnetHTA review, each
EPAR was evaluated by two HTA organizations from EUnetHTA.
Ten HTA organizations (see Acknowledgment) participated in this
exercise coordinated by the French National Authority for Health
(HAS). The results were calculated as mean values in terms of the
overall compliance rate across all 10 EPARs and reviewers for each
of the two organizations (i.e., if the answer for a binary question
was “yes” [“1”] in 6 out of 10 EPARs, a 60% overall compliance rate
was attributed). For descriptive purpose, the compliance rates are
clustered in three distinct categories: more than 80% compliance
(mean), 50% to 80% compliance (mean), and less than 50%
compliance (mean).Results
As a result of the project, the templates for preparing EPARs were
revised to address the comments received. Furthermore, a review
of a small set of EPARs was carried out in parallel by both
EUnetHTA and the EMA to ascertain whether these template
changes led to the inclusion of relevant information. The follow-
ing sections present these results separately.
Revision of Templates for Preparing EPARs
Figure 1 displays the development of revisions to templates for
regulatory assessments with the aim to improve the contribution
such reports can make to the assessment of relative effectiveness
of medicinal products. The initial analysis of a compilation of
comments from EUnetHTA/MEDEV identiﬁed 34 topic areas for
further discussion. These topics areas concerned the format and
structure, the scientiﬁc content, the evaluation criteria, and other
aspects of the assessment report. A detailed discussion of each
item revealed opportunities for improvement of template and
guidance as well as areas in which adherence to existing
template and guidance might need to be improved. Certain items
concerned the methodology for conducting an assessment rather
than data presentation, such as the acceptability of certain
surrogate parameters or the conduct of a wider literature search;
these items were excluded from the exercise. Most of the items,
which were addressed through revisions to the templates, con-
cerned the scientiﬁc content of the assessment report, partic-
ularly, the clinical aspects. In most instances, the agreed items
are related to a more detailed data presentation or more explicit
reasoning of considerations for the regulatory decision making.
In addition, speciﬁc sections of the SmPC have been identiﬁed in
Table 1 – Outcome of the review of compliance of EPARs with the template/guidance (N ¼ 10; categorization
based on mean values).*
Overall compliance
(%) accounted to
EUnetHTA review
Review item Overall compliance (%)
accounted to the EMA
review
o50 50–80 480 o50 50–80 480
Format and scientiﬁc content
X Table of contents† X
X List of abbreviations† X
X Clear referencing of data from publications† X
X Structural formula for chemical substances† X
X Structural characteristics for biologicals† X
X Description of standard treatments in the EU† X
X Discussion of compliance with legal requirements† X
X Discussion of compliance with scientiﬁc guidelines (EMA/CHMP)† X
X Discussion of compliance with scientiﬁc advice† X
X Discussion of outcome of any GCP inspection and its impact on data reliability† X
X Discussion of key elements of the study design: Patient population‡ X
X Discussion of key elements of the study design: Comparators‡ X
X Discussion of key elements of the study design: Duration of the study‡ X
X Discussion of key elements of the study design: End points and/or composite
end point‡
X
X Display of participant ﬂow (graphically or tabular)† X
X Summary of the main efﬁcacy data in the template table† X
X Explanation for reasoning for additional analyses, if requested‡ X
X Explanation if a subgroup data were considered of particular relevance for the
overall assessment of efﬁcacy‡
X
X Justiﬁcation for waiver of study or replacement by literature data‡ X
X Highlighting of shortcomings of the efﬁcacy data including impact on the
assessment‡
X
X Reﬂection of additional input from external experts (SAG, ad-hoc expert group,
PDCO), if requested‡
X
X Rationale for deciding that the risk-beneﬁt balance is positive is adequately
discussed‡,§
Support for summary of product characteristics (SmPC)||
X SmPC section 4.1: Reﬂection of approved therapeutic indication including
selection of patient population and age range, as applicable‡
X
X SmPC section 4.2: Substantiation of dose recommendations‡ X
X SmPC section 4.3: Substantiation of contraindications‡ X
X SmPC section 4.4: Substantiation of warning/precautions for use‡ X
X SmPC section 4.5: Substantiation of interaction statements‡ X
X SmPC section 4.6: Substantiation of use during pregnancy and lactation‡ X
X SmPC section 4.7: Substantiation of effects on ability to drive and use
machines‡
X
X SmPC section 4.8: Substantiation of adverse drug reaction proﬁle‡ X
X SmPC section 4.8: Deﬁnition of ADRs consistent between SmPC and
Assessment Report‡
X
X SmPC section 4.9: Substantiation of information on overdose‡ X
X SmPC section 5.1: Information on approved therapeutic indication(s) in line
with information in the Assessment Report‡
X
X SmPC section 5.1: Available data in the pediatric population‡ X
X SmPC section 5.2: Substantiation of pharmacokinetic properties‡ X
ADR, adverse drug reaction; CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; GCP, good clinical
practice; HTA, health technology assessment; EPAR, European Public Assessment Report; EU, European Union; EUnetHTA, European network
for Health Technology Assessment; PDCO, Paediatric Committee; SAG, Scientiﬁc Advisory Group.
* Because a separate reference listing is required only for EPARs with referencing to numerous publications and none of the EPARs subject to
the review did fulﬁll this criterion, the review item “separate reference listing” (planned to be reviewed using a binary question) was not
applicable and is therefore not reported in terms of compliance.
† Item reviewed using a binary question; i.e., the aspect is included “yes/no.”
‡ Item reviewed using a graded question; i.e., the aspect is included “excellent/good/could be improved/no.”
§ Item added by HTA organizations at the time of EUnetHTA review.
|| Only aspects of sections 4.1, 4.2, and 5.1 (Information on approved therapeutic indication) were topics speciﬁcally addressed through
revisions of template/guidance.
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Fig. 1 – Development of revisions to templates for regulatory assessments with the aim to improve the contribution such reports
can make to the assessment of relative effectiveness of medicinal products. CHMP, Committee for Medicinal Products for
Human Use; EMA, European Medicines Agency; EPAR, European Public Assessment Report; EU, European Union; EUnetHTA,
European network for Health Technology Assessment; PL, package leaﬂet; QC, quality control; SAG, Scientiﬁc Advisory Group.
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sion in the assessment report would be beneﬁcial.
The subsequent revisions concerned various parts of the
existing templates and guidance documents. In Figure 1, a tabular
overview of the revisions to the templates is provided, identifying
updates sections and describing the changes introduced. As an
example, for the discussion of key elements of the study design, a
new subsection was created in the “Discussion on clinical efﬁcacy”
of the assessment report. In this new subsection titled “Design andconduct of clinical studies,” a critical discussion should address
among others whether the design of the studies is deemed
adequate, the patient population was adequately selected, the
comparator considered appropriate, an active comparator was
relevant in view of EU-approved treatment options, and the choice
of end points and duration of study was adequate considering
regulatory guidance. To address the request for better explanation
of the reasoning for additional analysis, relevance of a particular
subgroup, and the appropriateness to waive studies or replace
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 3 4 – 6 4 1638these against literature data, speciﬁc guidance was provided in a
new subsection “Efﬁcacy data and additional analysis.”
A template table for a structured summary of the main
efﬁcacy data was developed jointly by the EMA and EUnetHTA
and has been newly introduced into the assessment reports.
Figure 2 shows this template together with the respective
guidance. The objective was to provide a tabulated summary
of the efﬁcacy data that were considered most relevant for the
regulatory decision making. For each of the main studies, a
separate table should be presented detailing the results accord-
ing to the prespeciﬁed analysis as well as any other analysis
that is deemed relevant. Because it is foreseen to allow for a
plain data presentation, this table should be read in conjunction
with the discussion and conclusion on clinical efﬁcacy, as wellFig. 2 – Template for the summary of main efﬁcacy data for the
ANOVA, analysis of variance; CHMP, Committee for Medicinal P
Regulating Authorities Clinical Trials; ISRCT, International Stand
mITT, modiﬁed intention to treat PP, per protocol.as the beneﬁt-risk assessment in later parts of the assessment
report.
Parallel Review of EPARs
The outcome of the review is presented in Table 1. For each
review item, the overall compliance with the template across all
10 EPARs is displayed in three categories. This is done separately
for the review by EUnetHTA and by the EMA to allow for an
overview of the ranking by each of the two organizations as well
as a comparison of the results between the two reviews.
With regard to the format of the EPAR, the two reviews
showed that a table of contents was always included whereas
individual publications were not always clearly referenced. Withregulatory assessment report with guidance (in italics).
roducts for Human Use; EudraCT, European Union Drug
ard Randomized Controlled Trial; ITT, intention to treat;
Fig. 2 – continued
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rate was assigned by both the EMA and EUnetHTA for the
presentation of patient ﬂow as graphic or table as well as the
newly introduced summary table of main efﬁcacy results and
analysis. However, low compliance rates were identiﬁed regard-
ing the presentation of discussion on the key elements of the
study design including patient populations, comparators, dura-
tion of the study, and end points, as also shown in Figure 3.
The explanation for reasoning of additional data analyses
requested by the CHMP as well as the emphasis on shortcoming of
the efﬁcacy data were highlighted by EUnetHTA as critical areas of
the clinical efﬁcacy discussion; the compliance according to
EunetHTA review was found below 50% on these two items. In
addition, explanations when a subgroup analysis is considered of
particular relevance, justiﬁcations for waiver or replacement of a stu-
dy by literature data, and reﬂection of additional input from externalexpert were also considered of particular importance. These review
items were moderately compliant from EUnetHTA perspective, con-
trary to EMA, which rated these items above 80% compliance, except
for the justiﬁcation for waiver or replacement of a study by literature
data (o50%). Regarding the additional item reviewed by EUnetHTA
only on the beneﬁt-to-risk assessment, a compliance rate indicating
satisfactory adherence to template guidance was documented.
The support of the SmPC through the assessment reports was
considered by EUnetHTA as appropriate for most of the review
items (between the range of 50% and 80%); however, none of them
was above 80%. Four items were reviewed below 50% of compliance,
notably for the substantiation of contraindications. The EMA attrib-
uted a compliance rate of 50% to 80% and more than 80% for 10 and
3 of these items, respectively. For 7 of the 13 review items including
the sections on therapeutic indication, dose recommendations
(particularly deviations from standard dose), and warnings and
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Fig. 3 – Compliance of EPARs with guidance in templates
regarding the presentation of discussion on the key
elements of study designs (N ¼ 10). EMA, European
Medicines Agency; EPAR, European Public Assessment
Report; EUnetHTA, European network for Health Technology
Assessment.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 3 4 – 6 4 1640precautions for use and interactions, the two organizations con-
cluded on 50% to 80% compliance. Speciﬁcally for the review items
stemming from the initial EUnetHTA/MEDEV comments, namely,
the reﬂection of approved therapeutic indication in section 4.1, the
substantiation of dose recommendations in section 4.2, and the
information on approved therapeutic indication(s) in section 5.1,
both reviews assigned a compliance category of 50% to 80%.Discussion
This joint project between the EMA and EUnetHTA aimed at
improving the contribution EPARs can make to the assessment of
relative effectiveness by European HTA bodies. EPARs are pub-
lished regulatory assessment reports supporting the licensing of
medicinal products that are centrally authorized in Europe. Given
the scope of the centralized procedure, almost all new therapeu-
tics (new molecular entities and biologics) receive their market-
ing authorization through this licensing route [7].
Based on observations on the usefulness of EPARs and SmPCs
from an HTA perspective, the EMA and EUnetHTA agreed on
speciﬁc items for improvement of the presentation of data and
information in the EPAR. The emphasis was on a better under-
standing of the regulatory judgment, such as critical discussions
of study design as well as speciﬁc subgroup analysis. Further-
more, a structured and harmonized presentation of main efﬁcacy
data was requested in view of clarity and transparency of the
data that is deemed most important from a regulatory perspec-
tive. Through changes in the templates and guidance documents
for assessment reports, these agreed topics were speciﬁcally
targeted. The revisions—if adhered to when writing the actual
reports—were aimed to ensure that the relevant data and
information are provided with the published documents.
The review of actual EPARs explored how well these revisions
are translated into practice. Using the same methodology, both
the EMA and EUnetHTA came to the view that the compliance
differs across various aspects in the assessment report. Given that
the EPAR format and scientiﬁc content showed overall high rates
of compliance with the revised templates, it can be assumed that
the quality of the documents has been improved even if no such
assessment of previous EPARs with the same methodology wasperformed to quantify the difference. An achievement was the
introduction of the tabular overview of main efﬁcacy data, which
was widely adhered to. Also, more structural aspects in the EPAR
were implemented. There remains, however, space for further
improvement in the critical discussion of the key elements of the
clinical study design, that is, on patient population (including
subpopulation and special populations), comparators, duration of
the study, end points, and/or composite end-point use. Some of
these aspects may be present in the clinical efﬁcacy discussion
but are not visible enough or not discussed enough. The sub-
stantiation of the SmPC was variable, with some areas requiring
special attention mainly for the sections concerning the dose
recommendations (particularly deviations from standard dose),
contraindications, warnings and precautions, and interactions.
The most divergent view between the reviews of the two
organizations seemed to be regarding the discussion of the
shortcomings of efﬁcacy data as well as the identiﬁcation and
explanation of additional analysis requested during the regulatory
review. These items are considered as critical areas of the clinical
efﬁcacy discussion from EUnetHTA perspective, as well as explan-
ations when a subgroup analysis is considered of particular
relevance, justiﬁcations for waiver or replacement of a study by
literature data, and reﬂection of additional input from an external
expert, which would beneﬁt being more clearly identiﬁed in the
content of the clinical efﬁcacy discussion and individually dis-
cussed. Looking into the responses, however, there might have
been different interpretations of the questions between the two
reviews. Importantly, aspects such as the request for additional
analysis, Good Clinical Practice (GCP) inspections, and external
expert consultations are discussed in the EPAR only if they
occurred and if they are recorded. EUnetHTA suggestion to the
EMA was to increase the granularity in the structure of the clinical
efﬁcacy discussion report template to address the main above-
mentioned aspects and make the information more visible.
It was also noted that there are different expectations with
regard to the referencing of literature because the regulatory
assessment is usually based on study reports rather than pub-
lished literature. In general, regulatory-speciﬁc terminology might
have been differently understood in some cases during the review
by EUnetHTA; for example, the term scientiﬁc guidelines in the
regulatory context usually refers to the guidance on the clinical
development program to support an application for marketing
authorization rather than to treatment recommendations. An
overall perception during the review by HTA bodies was that the
information was provided in the EPAR but on some occasions was
either difﬁcult to locate or not sufﬁciently discussed.
A limitation of the compliance review was that it was performed
with EPARs that were written immediately after the revised tem-
plates came into operation. This meant that the primary assessment
reports from assessors, which lead up to the ﬁnal CHMP assessment
report supporting the outcome of the regulatory review and hence
the EPAR, have not been prepared following these new standards.
Furthermore, the reviewwas limited to 10 EPARs andwas performed
by the two decision makers without involving a “third” party.
Nevertheless, the review highlighted important aspects that should
be subject to the quality review process of assessment reports in the
future. If subsequently areas are identiﬁed that can be improved
further in the templates and the guidance documents, these can be
implemented through the regular revision processes.Conclusions and Perspectives
With this collaboration the EMA and EUnetHTA responded to a
political recommendation to consider how the regulatory assess-
ment report about favorable and unfavorable effects of a medicine
can best be used in the assessment of the relative effectiveness of
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 3 4 – 6 4 1 641new medicines for HTA purposes in the EU member states. There
is growing international experience regarding aspects to be con-
sidered to optimize the interface between regulatory approval and
reimbursement decision [8]. The present work was the ﬁrst joint
project of such collaboration between regulators and HTA bodies
on a European level. The remit of both parties was respected
throughout the project and the focus was on the presentation of
data and information without entering into a discussion about
potentially divergent views on evidentiary standards. With the
improved presentation of data and information in the EPAR, it is
envisaged that this regulatory document through harmonized
efﬁcacy data presentation will be more useful in the context of
rapid REAs by HTA bodies when they inform policymakers and
health care decision makers in the future.
The initiation of the dialogue between the EMA and EUnetHTA
on the EPAR has demonstrated the opportunity to engage in
discussions about better exchange of data and information. In
fact, the parallel review of EPARs has been useful for each of the
organizations to not only critically review the end-product
“assessment report” using a predeﬁned methodology but also
mutually identify areas for future improvement.
The project has shown the pursuit of one opportunity for
regulators to proactively contribute information to the assess-
ment of relative (comparative) effectiveness by HTA bodies,
independent of jurisdiction. Beyond this project on EPARs, the
EMA and EUnetHTA are continuing to explore other areas of
collaboration or exchange of information. These include ways to
obtain scientiﬁc advice or early dialogues involving regulators and
HTAs/payers, exchange on scientiﬁc and methodological guide-
lines, topics in the area of postlicensing data generation, as well
as the particularities of orphan medicinal products [9]. The EMA’s
Road Map to 2015 identiﬁed the improvement of EPARs in view of
their use for HTAs as well as the EMA’s engagement with HTA
organizations—regarding drug development and evidential stand-
ards as well as postlicensing research and data collection—as
major initiatives [10]. Similarly, EUnetHTA has deﬁned collabo-
ration with EMA as a priority [11]. A joint EMA-EUnetHTA three-
year work plan 2013-2015 has recently been agreed [12]. Overall, it
is expected that this dialogue between regulators and HTA bodies
on a European level will continue to facilitate the bridging
between regulatory approval and access to market and will
provide important contributions to various health policy topics.Acknowledgments
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